Antimicrobial peptides: Coming to the end of antibiotic era, the most promising agents
Recently, because of the rising in multidrug resistance from infectious agents, there is a prompted interest for the development of new antimicrobial agents and new therapeutic strategies to combat the infections caused by the resistant bacteria. Among them, the natural bactericidal compounds, such as antimicrobial cationic peptides (AMPs) seems very promising agents. AMPs are the important component of the innate immune response to the surrounding microorganisms. This substances which can be isolated from most of the living organisms, have various activity like broad spectrum antibacterial, antifungal, antiviral, and antiprotozoal. However there are some resistance mechanisms that affects the AMPs, because of the rapid action and existing more than one mechanism of action, development of resistance to AMPs is quite rare. Due to their many advantages and characteristics, AMPs looks like a good candidate for being a new generation, active antimicrobial agent for antimicrobial chemotherapy against especially multi drug resistant bacteria and biofilms, either alone or in combination.
___
- • Akova M (2016) Epidemiology of antimicrobial resistance in
bloodstream infections, Virulence, 7: 252-266. [CrossRef]
• Bechinger B, Lohner K (2006) Detergent-like actions of linear
amphipathic cationic antimicrobial peptides, Biochim Biophys
Acta., 1758: 1529-1539. [CrossRef]
• Cao Y, Yu RQ, Liu Y, Zhou HX, Song LL, Cao Y, Qiao DR (2010)
Design, recombinant expression, and antibacterial activity of
the cecropins-melittin hybrid antimicrobial peptides, Curr. Microbiol.,
61: 169-175. [CrossRef]
• Donadio S, Maffioli S, Monciardini P, Sosio M, Jabes D (2010) Antibiotic
discovery in the twenty-first century: current trends and
future perspectives, J Antibiot., 63: 423-430. [CrossRef]
• Donlan RM (2001) Biofilm formation: a clinically relevant microbiological
process, Clin Infect Dis., 33: 1387–1392. [CrossRef]
• Dosler S, Karaaslan E (2014) Inhibition and destruction of Pseudomonas
aeruginosa biofilms by antibiotics and antimicrobial
peptides, Peptides, 63: 32-37. [CrossRef]
• Dosler S, Mataraci E (2013) In vitro pharmacokinetics of antimicrobial
cationic peptides alone and in combination with
antibiotics against methicillin resistant Staphylococcus aureus
biofilms, Peptides, 49: 53-58. [CrossRef]
• Felício MR, Silva ON, Gonçalves S, Santos NC, Franco OL (2017)
Peptides with dual antimicrobial and anticancer activities, Front
Chem, 5: 1-9. [CrossRef]
• Findlay F, Proudfoot L, Stevens C, Barlow PG (2016) Cationic
host defense peptides; novel antimicrobial therapeutics against
Category A pathogens and emerging infections, Pathog Glob
Health, 110: 137-147. [CrossRef]
• Giamarellou H (2010) Multidrug-resistant gram-negative bacteria:
how to treat and for how long, International Journal of Antimicrobial
Agents, 36: S50–S54. [CrossRef]
• Griffith GL, Kasus-Jacobi A, Pereira HA (2017) Bioactive antimicrobial
peptides as therapeutics for corneal wounds and infections,
Adv Wound Care (New Rochelle), 6: 175-190. [CrossRef]
• Guilhelmelli F, Vilela N, Albuquerque P, Derengowski Lda S, Silva-
Pereira I, Kyaw CM (2013) Antibiotic development challenges:
the various mechanisms of action of antimicrobial peptides of
bacterial resistance, Front Microbiol, 4: 1-12. [CrossRef]
• Hancock RE (2001) Cationic peptides: effectors in innate immunity
and novel antimicrobials, Lancet Infect Dis, 1: 156-164.
[CrossRef]
• Hancock RE, Sahl HG (2006) Antimicrobial and host-defense
peptides as new anti-infective therapeutic strategies, Nat. Biotechnol,
24: 1551-1557. [CrossRef]
• Hancock RE., Chapple DS (1999) Peptide antibiotics, Antimicrob
Agents Chemother., 43: 1317-1323.
• Høiby N, Bjarnsholt T, Givskov M (2010) Antibiotic resistance of bacterial
biofilms, Int L Antimicrob Agents, 35: 322-332. [CrossRef]
• Jenssen H, Hamill P, Hancock RE (2006) Peptide antimicrobial
agents, Clin Microbiol Rev, 19: 491-511. [CrossRef]
• Jorge P, Lourenço A, Pereira MO (2012) New trends in peptidebased
anti-biofilm strategies: a review of recent achievements
and bioinformatic approaches, Biofouling, 28: 1033-1061.
[CrossRef]
• McCafferty DG, Cudic P, Yu MK, Behenna DC, Kruger R (1999)
Synergy and duality in peptide antibiotic mechanisms, Curr
Opin Chem Biol, 3: 672-680. [CrossRef]
• Mendez-Samperio P (2013) Recent advances in the field of antimicrobial
peptides in inflammatory diseases, Adv Biomed Res, 2:50-55.
[CrossRef]
• Naim H, Rizvi M, Azam M, Gupta R, Taneja N, Shukla I, Khan HM
(2017) Alarming emergence, molecular characterization, and
outcome of blaNDM-1 in patients infected with multidrugresistant
Gram-negative bacilli in a tertiary care hospital, J Lab
Physicians, 9: 170-176. [CrossRef]
• Nawrocki KL, Crispell EK, McBride SM (2014) Antimicrobial Peptide
Resistance Mechanisms of Gram-Positive Bacteria, Antibiotics
(Basel), 3: 461–492. [CrossRef]
• Otvos L. Jr (2005) Antibacterial peptides and proteins with multiple
cellular targets, J Peptide Sci, 11: 697–706. [CrossRef]
• Raghuraman H, Chattopadyay A (2007) Melittin: a membraneactive
peptide with diverse function, Biosci Rep, 27: 189-223.
[CrossRef]
• Rosenthal VD, Al-Abdely HM, El-Kholy AA, AlKhawaja SA, Leblebicioglu
H, Mehta Y, Rai V, et al (2016) International Nosocomial
Infection Control Consortium report, data summary of 50
countries for 2010-2015: Device-associated modüle, Am J Infect
Control, 44: 1495-1504. [CrossRef]
• Sawyer JG, Martin NL, Hancock REW (1988) Interaction of macrophage
cationic proteins with the outer membrane of Pseudomonas
aeruginosa, Infect Immun, 56: 693-698.
• Selsted ME, Novotny MJ, Morris WL, Tang YQ, Smith W, Cullor
JS (1992) Indolicidin, a novel bactericidal tridecapeptide amide
from neutrophils, J. Biol. Chem, 267: 4292-4295.
• Seo MD, Won HS, Kim JH, Mishig-Ochir T, Lee BJ (2012) Antimicrobial
peptides for therapeutic applications: a review, Molecules.
17: 12276-12286. [CrossRef]
• Steinberg DA, Hurst MA, Fujii CA, Kung AH, Ho JF, Cheng FC et
al (1997) Protegrin-1: a broad- spectrum, rapidly microbicidal
peptide with in vivo activity, Antimicrob Agents Chemother, 41:
1738-1742.
• Wang G, Mishra B, Lau K, Lushnikova T, Golla R, Wang X (2015) Antimicrobial
Peptides in 2014, Pharmaceuticals, 8: 123-150. [CrossRef]
• Wang G (2015) Improved methods for classification, prediction,
and design of antimicrobial peptides, Methods Mol Biol, 1268: 43-
66. [CrossRef]
• Willey JM, Van der Donk WA (2007) Lantibiotics: peptides of diverse
structure and function, Annu. Rev. Microbiol, 61: 477–501.
[CrossRef]
• World Health Organization (2014) Antimicrobial resistance: global
report on surveillance 2014, Geneva, Switzerland: WHO.
• World Health Organization (2015) Antimicrobial resistance. Draft
global action plan on antimicrobial resistance, Geneva, Switzerland:
WHO.
• Yeaman MR, Yount NY (2003) Mechanisms of antimicrobial peptide
action and resistance, Pharmacol Rev, 55: 27-55. [CrossRef]
• Yeung AT, Gellatly SL, Hancock RE (2011) Multifunctional cationic
host defence peptides and their clinical applications, Cell Mol Life
Sci, 68: 2161-2176. [CrossRef]